Skip to main content
. 2018 Aug 24;18(5):4410–4416. doi: 10.3892/mmr.2018.9428

Figure 3.

Figure 3.

TSLP increases the number of Bcl-2+ ESCs without affecting the expression Fas or FasL in ESCs. (A and B) Expression of Bcl-2 in ESCs was detected by FCM following treatment with rhTSLP (0, 1, 10 or 100 ng/ml) or αTSLP (0.25 µg/ml). (C) Expression of Fas and FasL in ESCs was detected within ESCs under the same processing conditions. The data are expressed as the mean ± standard error of the mean. *P<0.05 or **P<0.01 vs. Ctrl group. Bcl-2, B-cell lymphoma 2; Ctrl, control; ESCs, endometrial stromal cells from patients with endometriosis; FasL, Fas ligand; NS, not significant; rhTSLP, recombinant human thymic stromal lymphopoietin; αTSLP, anti-human TSLP neutralizing antibody.